Catamaran Bio appoints new CMO



Biotech company Catamaran Bio has announced the appointment of Cherry Thomas, MD, as Chief Medical Officer (CMO).

Catamaran develops off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer.

Dr Thomas has extensive pharmaceutical and biotech industry experience and expertise in the clinical development of oncology therapeutics including allogeneic cell therapies.

The CMO initiated a first-in-human clinical trial of an allogeneic cell therapy during her previous role as senior vice president of clinical development at Caribou Biosciences.

Dr Thomas also held senior roles in oncology clinical development at Array BioPharma/Pfizer, Bristol Myers Squibb, Novartis, GlaxoSmithKline and Amgen.

Alvin Shih, MD, Chief Executive Officer of Catamaran Bio, said:

“Cherry’s extensive experience in oncology and cell therapy drug development, clinical expertise, and impressive track record make her an ideal fit as we advance our innovative CAR-NK programs.

“We welcome Cherry at a pivotal time in our evolution, as we build the capabilities to become a clinical-stage company.”

Dr Thomas said: “I am excited to bring my clinical development experience with allogeneic cell therapies to a talented Catamaran team that has built a leading-edge platform for CAR-NK cell therapies.

“I look forward to the opportunity to guide the clinical advancement of the Catamaran’s promising pipeline of allogeneic CAR-NK cell therapies, potentially becoming off-the-shelf treatments for patients with solid tumours.”

Dr Thomas received her MD from the University of California, Irvine, and completed her residency at the University of Michigan in radiation oncology and is a licensed physician and surgeon. She received her BA from the University of California, Los Angeles.

Click to comment

Trending stories

Exit mobile version